Dual GIP/GLP-1 Receptor Agonist
Zepbound®(Tirzepatide)
FDA-Approved Specifically for Weight Loss
Zepbound® (tirzepatide) is FDA-approved specifically for chronic weight management—the same powerful dual-action medication as Mounjaro, now with official weight loss approval.
Avg weight loss
20-22%
vs retail
74%
up to 74% savings vs ~$1050/mo retail
Frequency
Once Weekly
Most patients start at $275/mo. Some starting options are as low as $149/mo. Final pricing is set with your provider during your consultation.
How Zepbound works
Zepbound activates both GIP and GLP-1 receptors, creating a dual-action effect that surpasses traditional single-receptor weight loss medications. It reduces hunger signals, increases feelings of fullness, slows digestion, and improves how your body processes food—all working together for maximum weight loss.
Clinical evidence: The SURMOUNT trials showed participants on Zepbound lost an average of 22.5% of their body weight—approximately 52 pounds for the average participant—making it the most effective FDA-approved weight loss medication.
Benefits at PWL
- FDA-approved specifically for weight loss
- Highest average weight loss of any approved medication (20-22%)
- Dual GIP/GLP-1 mechanism for superior results
- Once-weekly convenient injection
- Dramatic reduction in hunger and cravings
- Improvements in blood pressure and cholesterol
- Better energy levels as weight decreases
- Reduced risk of weight-related diseases
Common side effects
- Nausea (most common in first weeks, typically resolves)
- Diarrhea or vomiting
- Constipation
- Abdominal discomfort
- Injection site reactions
Side effects are typically mild and improve over time. Your provider will guide you on managing any symptoms during your monthly check-ins.